Amgen (NASDAQ:AMGN) Issues FY 2024 Earnings Guidance

Amgen (NASDAQ:AMGNGet Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 19.200-20.000 for the period, compared to the consensus earnings per share estimate of 19.490. The company issued revenue guidance of $33.0 billion-$33.8 billion, compared to the consensus revenue estimate of $33.2 billion. Amgen also updated its FY24 guidance to $19.20-$20.00 EPS.

Analyst Ratings Changes

Several brokerages have weighed in on AMGN. Bank of America upped their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. TD Cowen increased their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Morgan Stanley reduced their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Finally, Oppenheimer restated an “outperform” rating and set a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $332.55.

Get Our Latest Stock Report on Amgen

Amgen Stock Down 0.1 %

AMGN traded down $0.46 during trading on Wednesday, reaching $315.54. The company had a trading volume of 2,208,707 shares, compared to its average volume of 2,419,429. The company has a market cap of $169.27 billion, a P/E ratio of 45.14, a PEG ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen has a 12 month low of $249.70 and a 12 month high of $346.85. The business’s fifty day moving average price is $325.02 and its 200 day moving average price is $314.78.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the company earned $5.00 earnings per share. Equities analysts anticipate that Amgen will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 2.85%. Amgen’s payout ratio is currently 128.57%.

Amgen Company Profile

(Get Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read More

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.